CN107274317A - Medical institutions' economics information processing method - Google Patents
Medical institutions' economics information processing method Download PDFInfo
- Publication number
- CN107274317A CN107274317A CN201710489211.XA CN201710489211A CN107274317A CN 107274317 A CN107274317 A CN 107274317A CN 201710489211 A CN201710489211 A CN 201710489211A CN 107274317 A CN107274317 A CN 107274317A
- Authority
- CN
- China
- Prior art keywords
- information
- disease
- dosage regimen
- rule set
- medical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000003672 processing method Methods 0.000 title claims abstract description 11
- 230000010365 information processing Effects 0.000 title claims description 5
- 239000003814 drug Substances 0.000 claims abstract description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 27
- 201000010099 disease Diseases 0.000 claims abstract description 26
- 229940079593 drug Drugs 0.000 claims abstract description 19
- 238000011156 evaluation Methods 0.000 claims abstract description 11
- 241001269238 Data Species 0.000 claims abstract description 8
- 238000012545 processing Methods 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims description 12
- 230000001225 therapeutic effect Effects 0.000 claims description 9
- 238000004458 analytical method Methods 0.000 claims description 8
- 238000012043 cost effectiveness analysis Methods 0.000 claims description 6
- 238000001647 drug administration Methods 0.000 claims description 5
- 230000008859 change Effects 0.000 claims description 3
- 238000013480 data collection Methods 0.000 claims description 2
- 230000003993 interaction Effects 0.000 claims description 2
- 230000006651 lactation Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 206010043431 Thinking abnormal Diseases 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 239000009692 xuesetong Substances 0.000 description 3
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- KINGXFAMZNIVNL-SXQDSXCISA-N safflor yellow A Natural products OC[C@@H]1O[C@H]2[C@H](OC3=C2C(=O)C(=C(O)C=Cc4ccc(O)cc4)C(=O)[C@]3(O)[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)[C@@H](O)[C@H]1O KINGXFAMZNIVNL-SXQDSXCISA-N 0.000 description 2
- 239000008354 sodium chloride injection Substances 0.000 description 2
- WLYGSPLCNKYESI-RSUQVHIMSA-N Carthamin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@@]1(O)C(O)=C(C(=O)\C=C\C=2C=CC(O)=CC=2)C(=O)C(\C=C\2C([C@](O)([C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(O)=C(C(=O)\C=C\C=3C=CC(O)=CC=3)C/2=O)=O)=C1O WLYGSPLCNKYESI-RSUQVHIMSA-N 0.000 description 1
- DYQVDISPPLTLLR-HJQYTNQXSA-N Carthamin Natural products CC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@]2(O)C(=C(C=C/3C(=O)C(=C(O)[C@](O)([C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C3=O)C(=O)C=Cc5ccc(O)cc5)C(=O)C(=C2O)C(=O)C=Cc6ccc(O)cc6)O DYQVDISPPLTLLR-HJQYTNQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000010206 sensitivity analysis Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Information and communication technology [ICT] specially adapted for implementation of business processes of specific business sectors, e.g. utilities or tourism
- G06Q50/10—Services
- G06Q50/22—Social work or social welfare, e.g. community support activities or counselling services
Landscapes
- Business, Economics & Management (AREA)
- Tourism & Hospitality (AREA)
- Health & Medical Sciences (AREA)
- Primary Health Care (AREA)
- Economics (AREA)
- General Health & Medical Sciences (AREA)
- Human Resources & Organizations (AREA)
- Marketing (AREA)
- Child & Adolescent Psychology (AREA)
- Strategic Management (AREA)
- Physics & Mathematics (AREA)
- General Business, Economics & Management (AREA)
- General Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Theoretical Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to a kind of processing method of pharmacoeconomics information, including：Obtain the patient medication data of medical institutions；Accordance judgement is carried out to administration data using disease dosage regimen rule set, the different dosage regimen medical datas of disease are obtained if meeting；It is made whether that reasonability judges to dosage regimen medical data using rational use of medicines rule set, if it is obtains the different dosing regimes target medical data of disease；Pharmacoeconomic evaluation, which is carried out, using dosage regimen target medical data obtains pharmacoeconomics information.The processing method of pharmacoeconomics information of the present invention can efficiently, fast and accurately carry out the processing of pharmacoeconomics information.
Description
Technical field
The present invention relates to field of information processing, and in particular to a kind of medical institutions' economics information processing method.
Background technology
Patients ' demand and medical resource are permanently present contradiction, are on the one hand the rapid expansions of patients ' demand, it is desirable to use most
Good, newest and most expensive medicine, is on the other hand the limited ability to bear of government's guarantee system, it is desirable to reasonable price, is fitted
Preferably, the problem of then must just proposing rationally to apply to medical resource.It is exactly asking for the rational use of medicines specific to medicine using upper
Topic.The rational use of medicines is：Safely, effectively, economical, this requires in the selecting of medicine, fixes a price, the link such as use, and is considering medicine
On the basis of the securities of product, validity, it is necessary to take into full account economy, that is, Cost Problems.If safely, effectively
It is medicine " performance ", economy is " price ", then it is clear that our the maximally effective evaluation indexes in assessing drug actions are exactly
" cost performance ", and pharmacoeconomics is exactly to solve the problems, such as medicine cost performance.
But do not have the processing method of a pharmacoeconomics information in the prior art.
The content of the invention
The purpose of the present invention be the defect for prior art there is provided a kind of processing method of pharmacoeconomics information, with
Realize the processing for efficiently, fast and accurately carrying out pharmacoeconomics information.
To achieve the above object, the invention provides a kind of processing method of pharmacoeconomics information, method includes：Step
1, obtain the patient medication data of medical institutions；
Step 2, accordance judgement is carried out to administration data using disease dosage regimen rule set, step 3 is performed if meeting；
Step 3, the different dosage regimen medical datas of disease are obtained；Step 4, using rational use of medicines rule set to dosage regimen medical treatment
Data are made whether that reasonability judges, if it is perform step 5；Step 5, the different dosing regimes target medical treatment of disease is obtained
Data；Step 6, carry out pharmacoeconomic evaluation using dosage regimen target medical data and obtain pharmacoeconomics information.
The processing method of pharmacoeconomics information of the present invention can efficiently, fast and accurately carry out pharmacoeconomics information
Processing, quickly filter out satisfactory case information according to research purpose, and reject the case letter of Irrational Use of Drugs
Breath.
Embodiment
Below by embodiment, technical scheme is described in further detail.
The present invention specifically includes following steps：
Obtain the patient medication data of medical institutions；Accordance judgement is carried out to administration data using disease dosage regimen rule set
。
Disease dosage regimen refers in clinical treatment, in order to reach the purpose of the rational use of medicines, according to the concrete condition of patient and
The pharmacodynamics of medicine and the scheme information of pharmacokinetics feature proposed treatment, including types of drugs combination, drug administration dosage, administration
The plan of frequency, drug administration approach, drug delivery regimen, the order of administration of different pharmaceutical breed combination and dosing interval etc..
Disease dosage regimen rule set is specially that the regular collection after symbolism processing is carried out to therapeutic scheme.
Handle, lead to by disease dosage regimen rule set so all administration datas can also be included before step 101
Simulation judgement processing is crossed, according to logic judgment rule, is believed using patient demographic, disease information, operation/operation
The medical treatment of disease different dosing regimes is formed after breath, drug administration information, condition and record that rule whether is met to therapeutic scheme information
Data set.
Specifically, disease dosage regimen rule set is that the regular collection after symbolism is carried out to therapeutic scheme.All medical treatment
When the administration data of mechanism passes through disease dosage regimen rule set, system simulates critical thinking process, root by intellgence reasoning machine
According to the logic judgment rule set up in system, patient demographic, disease information, operation/operation information, drug administration information are utilized
Etc. result, the condition of rule whether is met to therapeutic scheme (including operation/operation scheme, therapeutic regimen), system background can be certainly
It is dynamic to record these information, form disease different dosing regimes medical data collection.
Wherein therapeutic scheme Knowledge Source in：(1) existing practice guidelines or document；(2) medical data is through expert judgments
Relatively reasonable protocol step 103 is crossed, it is total using medical data for removing non-essential medical data in administration data
Knot information performs step 102 after being handled；Step 104, the different dosage regimen medical datas for obtaining disease；Step 105,
It is made whether that reasonability judges to dosage regimen medical data using rational use of medicines rule set, if otherwise deleting irrational medical orders
The medical data of single patient, if it is performs step 6；Rational use of medicines rule set is used for the reasonability judgement to single medicine,
Specifically include usage and dosage, delivery time, method of administration, interaction, special population such as motherhood, lactation, the elderly's taboo letter
Breath.Knowledge Source then package insert, clinical application notice or treatment guidelines etc..
Step 106, the different dosing regimes target medical data of disease is obtained；
Step 107, carry out pharmacoeconomic evaluation using dosage regimen target medical data and obtain pharmacoeconomics information.
Pharmacoeconomic evaluation is carried out using dosage regimen target medical data to specifically include：Cost-effectiveness analysis and into
Sheet-utility analysis.
Before Pharmacoeconomics analysis is to determine that evaluation purpose, analytic angle and alternative are with the basic step evaluated
Carry, specify all foreseeable benefits, effectiveness and effect in each scheme, and it is measured as far as possible, while carrying out cost
Estimation, sensitivity analysis etc., are finally compared using correlation method, A+E to each scheme, in conjunction with feasibility
The decision-making of science is made in analysis and policy analysis.Therefore, Pharmacoeconomic Evaluation is exactly by the cost of different schemes, result (bag
Include effect, effectiveness and benefit) com-parison and analysis is carried out, reach the purpose for selecting optimal case.
Cost-effectiveness analysis (CEA)：It is with specific clinical treatment purpose (physiological parameter, functional status, increasing longevity year etc.)
For measurement index, the cost used in the per unit therapeutic effect of different schemes or therapy is calculated.The result of cost-effectiveness is not
Represented with monetary unit, and usually using healthy result or clinical treatment index, such as rescue patient's number, cure rate, extension
The change of the indexs such as life years, blood pressure decreasing value.
Cost-utility Analysis (CUA)：It is item compared input cost amount and the health-benefiting quantum of output through Mass adjust- ment,
Its use quality adjusts life years (QALY) as the evaluation unit of project health outcome.It is by calculating different schemes or therapy
Cost-effectiveness ratio, relatively each scheme or therapy obtain the cost that the QALY of per unit is consumed, and then to different efficiency
Make an appraisal.
Cost refers to the thing consumed during a certain production, service etc. in cost-effectiveness analysis and Cost-utility Analysis
Change the monetary value of work and flexibe work(labour).Characteristic at cost can be divided：Direct cost and indirect cost.
Increment effectiveness is selected for example, to compare traditional Chinese medicine treatment apoplexy cost-effectiveness analysis based on medical data：
Current Clinical practice has three dosage regimens, and " Xuesaitong Injection " group (A groups), carthamin yellow group (B groups), thrombus leads to group (C groups).
Go out this following 3 apoplexy case traditional Chinese medicine treatment group A groups using disease dosage regimen rule set examination to give
Panax notoginseng saponins for injection 400mg drip-feeds；B groups give Safflower Yellow Injection 100mg drip-feeds；C groups, which are given, to be noted
Penetrate and lead to 450mg drip-feeds with thrombus, treatment course reaches 14 days.Routinely give Thrombolytic Drugs, anticoagulation, cerebral protective agent simultaneously
Deng immunotherapy targeted autoantibody.
This 3 groups of case group patient medical datas are formed into a data set.The rational use of medicines is carried out through rational use of medicines rule set
Examine, reject the medical data of the irrational patient of solvent, such as A groups panax notoginseng saponins for injection is not selected dilute in 5% glucose 250mL
Release；B groups Safflower Yellow Injection does not select 0.9% sodium chloride injection 250mL to dilute；C group injections thrombus is logical not to be selected
0.9% sodium chloride injection 250mL dilutes.
The 3 case group patient medical datas collection retained imported into pharmacoeconomics computing unit, through statistical analysis, 3
Case group patient age, sex not significant difference are organized, then carries out Pharmacoeconomic Evaluation.A group " Xuesaitong Injection "s group is selected to commonly use
Therapeutic scheme, only selection calculates the medicine cost that " Xuesaitong Injection " is used, and average unit cost is 1030.4 yuan；Average curative effect is 85.37%
(curative effect is pressed after 14 days《Chinese medical disease Standardization of diagnosis and curative effect》Evaluation curative effect is carried out according to medical record result.Cure：Symptom and sign disappear
Lose, can live on one's own life substantially；Take a turn for the better：Symptom and sign take a turn for the better, and energy cane action, or basic living can take care of oneself；It is not cured：Symptom and
Sign is unchanged.) B groups average unit cost be 1876.0 yuan；Average curative effect is 88.57%；C groups average unit cost is 1545.6 yuan；It is flat
Equal curative effect is 90.04%, and threshold value certainly is respectively 264.25 yuan and 110.32 yuan, if setting 150 yuan as pharmacoeconomics of the present invention
The processing method of information can efficiently, fast and accurately carry out the processing of pharmacoeconomics information, quickly be sieved according to research purpose
Satisfactory case information is selected, and rejects the case information of Irrational Use of Drugs.
[professional should further appreciate that, with reference to each example of the embodiments described herein description
Unit and algorithm steps, can be realized with electronic hardware, computer software or the combination of the two, in order to clearly demonstrate
The interchangeability of hardware and software, generally describes the composition and step of each example according to function in the above description
Suddenly.
These functions are performed with hardware or software mode actually, depending on technical scheme application-specific and design about
Beam condition.
Professional and technical personnel can realize described function to each specific application using distinct methods, still
This realization is it is not considered that beyond the scope of this invention.
The method that is described with reference to the embodiments described herein can use hardware, computing device the step of algorithm
Software module, or the two combination are implemented.Software module can be placed in random access memory (RAM), internal memory, read-only storage
(ROM), electrically programmable ROM, electrically erasable ROM, register, hard disk, moveable magnetic disc, CD-ROM or technical field
In any other form of storage medium well known to interior.
Claims (5)
1. a kind of medical institutions' economics information processing method, it is characterised in that method includes：
Step 1, the patient medication data of medical institutions are obtained；
Step 2, accordance judgement is carried out to administration data using disease dosage regimen rule set, step 3 is performed if meeting；
Step 3, the different dosage regimen medical datas of disease are obtained；
Step 4, it is made whether that reasonability judges to dosage regimen medical data using rational use of medicines rule set, if it is performs
Step 5；
Step 5, the different dosing regimes target medical data of disease is obtained；
Step 6, carry out pharmacoeconomic evaluation using dosage regimen target medical data and obtain pharmacoeconomics information.
2. method according to claim 1, it is characterised in that disease dosage regimen rule set is specially to be accorded with to therapeutic scheme
Regular collection after number change processing.
3. method according to claim 2, it is characterised in that also include before step 1, all administration datas are administered by disease
The processing of scheme rule set, is handled by simulating judgement, according to logic judgment rule, utilizes patient demographic, disease
Disease is formed after information, operation/operation information, drug administration information, condition and record that rule whether is met to therapeutic scheme information
Different dosing regimes medical data collection.
4. method according to claim 1, it is characterised in that rational use of medicines rule set is used to sentence the reasonability of single medicine
It is disconnected, specifically include usage and dosage, delivery time, method of administration, interaction, special population such as motherhood, lactation, the elderly's taboo
Information.
5. method according to claim 1, it is characterised in that carry out pharmacoeconomics using dosage regimen target medical data and comment
Estimate and specifically include：Cost-effectiveness analysis and Cost-utility Analysis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710489211.XA CN107274317A (en) | 2017-06-24 | 2017-06-24 | Medical institutions' economics information processing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710489211.XA CN107274317A (en) | 2017-06-24 | 2017-06-24 | Medical institutions' economics information processing method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107274317A true CN107274317A (en) | 2017-10-20 |
Family
ID=60069584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710489211.XA Pending CN107274317A (en) | 2017-06-24 | 2017-06-24 | Medical institutions' economics information processing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107274317A (en) |
-
2017
- 2017-06-24 CN CN201710489211.XA patent/CN107274317A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Malahias et al. | Platelet‐rich plasma ultrasound‐guided injection in the treatment of carpal tunnel syndrome: A placebo‐controlled clinical study | |
| Frawley et al. | Women's use and self-prescription of herbal medicine during pregnancy: an examination of 1,835 pregnant women | |
| Abedi et al. | Breastfeeding or nipple stimulation for reducing postpartum haemorrhage in the third stage of labour | |
| Papakostas et al. | Long-term outcomes after proton beam irradiation in patients with large choroidal melanomas | |
| Rajkowska et al. | Neuronal and glial somal size in the prefrontal cortex: a postmortem morphometric study of schizophrenia and Huntington disease | |
| CN106372431B (en) | The processing method of therapeutic regimen information | |
| Muehlematter et al. | FDA-cleared artificial intelligence and machine learning-based medical devices and their 510 (k) predicate networks | |
| Bhattacharya et al. | Can patient-reported outcomes be used instead of clinician-reported outcomes and photographs as primary endpoints of late normal tissue effects in breast radiotherapy trials? Results from the IMPORT LOW trial | |
| Devinsky et al. | Preventing sudden unexpected death in epilepsy | |
| Hill et al. | Evaluation, treatment, and outcomes of suprascapular neuropathy: a 5-year review | |
| Wang et al. | The prognostic value of the Barthel index for mortality in patients with COVID-19: a cross-sectional study | |
| Beyt et al. | Prospective payment and infection control | |
| Jyotheeswar et al. | Prediction of Diabetic Retinopathy using Novel Decision Tree Method in Comparison with Support Vector Machine Model to Improve Accuracy | |
| White et al. | Interventions for fatigue in peripheral neuropathy | |
| CN107274317A (en) | Medical institutions' economics information processing method | |
| Luo et al. | [Retracted] Value of Humanized Nursing under Emergency Green Channel on Gastrointestinal Function Recovery in Patients with Acute Intestinal Obstruction after Operation | |
| CN106372429A (en) | Pharmacoeconomics information processing method | |
| Chodick et al. | Risk of cataract extraction among adult retinoblastoma survivors | |
| Finkelstein et al. | Data mining approaches to identify predictors of frequent malpractice claims against dentists | |
| Caselli et al. | Progressive apraxia in clinically discordant monozygotic twins | |
| Eisenstein et al. | Estimating clinical trial bleeding events using electronic health record data | |
| Etgü | Retrospective Analysis of Liver Enzyme Abnormalities in Patients Prescribed Terbinafine and Itraconazole for Onychomycosis | |
| Dong et al. | Artificial Intelligence-based Predictive Model for Guidance on Treatment Strategy Selection in Oral and Maxillofacial Surgery | |
| Teja et al. | Improving the Efficiency of Heart Disease Prediction Using Novel Random Forest Classifier Over Support Vector Machine Algorithm | |
| Patibandla | A Review on the Detection of the Post COVID-19 Symptoms for Long Term Diseased Patients using Machine Learning Algorithms |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20171020 |